A phase I study of the vitamin D(3) analogue ILX23-7553 administered orally to patients with advanced solid tumors.
Summary of "A phase I study of the vitamin D(3) analogue ILX23-7553 administered orally to patients with advanced solid tumors."
Purpose ILX23-7553 (1,25-dihydroxy-16-ene-23-yne vitamin D3) is a vitamin D analogue that was developed to avoid the hypercalcemia that may limit the use of vitamin D as an anti-cancer agent. We performed a phase I study of ILX23-7553 to determine its side-effect profile, pharmacokinetics, and to document any observed antitumor activity. Patients and Methods Adult patients with refractory solid tumors were enrolled. A modified Fibonacci dose escalation scheme was employed. ILX23-7553 was administered orally daily for three consecutive days, and repeated in 7-day cycles. Plasma drug concentrations were assayed by radioimmunoassay and radioreceptor assay. Results Sixteen patients were enrolled to 10 dose levels ranging from 1.7 to 37.3 mug/m(2)/day. The maximum tested dose was six times higher than the maximally-tolerated dose (MTD) in dogs. Dose-limiting toxicity was not observed. ILX23-7553 concentrations on cycle 1 day 1 of treatment were comparable to concentrations on cycle 2 day 1, suggesting limited accumulation. One patient with adrenal cortical cancer had stable disease for 23 weeks, but no objective responses were observed. Conclusions ILX23-7553 was well tolerated at the doses tested, with no evidence of hypercalcemia. The plasma concentrations achieved were approximately 100-fold lower than those associated with tumor growth inhibition in vitro, limiting use of this formulation.
Affiliation
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Journal Details
This article was published in the following journal.
Name: Investigational new drugs
ISSN: 1573-0646
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20661623
- DOI: http://dx.doi.org/10.1007/s10637-010-9492-5
Medical and Biotech [MESH] Definitions
Vitamin K
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
Contraceptives, Oral, Sequential
Drugs administered orally and sequentially for contraceptive purposes.
Contraceptives, Oral, Combined
Fixed drug combinations administered orally for contraceptive purposes.
Bufexamac
A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.
Interphase
The interval between two successive CELL DIVISIONS during which the CHROMOSOMES are not individually distinguishable. It is composed of the G phases (G1 PHASE; G0 PHASE; G2 PHASE) and S PHASE (when DNA replication occurs).
PubMed Articles
We investigated the effects of vitamin C administration on vitamin C-specific transporters in ODS/ShiJcl-od/od rat livers. The vitamin C-specific transporter levels increased in the livers of the rats...
Vitamin D receptor (VDR) antagonists have therapeutic potential in treatment of allergic conditions and hypercalcemia driven by granulomatous diseases. We have identified an o-aminoanilide analogue of...
A comparative study of antioxidant vitamins and simvastatin in hypercholesterolimic rabbits.
The anti-lipidemic effects of orally administered antioxidant vitamins (vitamin A, vitamin C and vitamin E) individually and in combination were studied in cholesterol-fed rabbits and compared to the...
In a previous study, we confirmed that orally administered l-ornithine can be transported into the brain of mice. In addition, orally administered l-ornithine, within a limited dose range, had an anxi...
Purpose CYT997 is a novel microtubule inhibitor and vascular disrupting agent. This phase I trial examined the safety, tolerability, pharmacokinetics and vascular-disrupting effects of orally-administ...
Clinical Trials
ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: ILX23-7553 may help solid tumor cells develop into normal cells. PURPOSE: Phase I trial to study the effectiveness of ILX23-7553 in treating patients who have solid tumors that...
Vitamin D and Genetics in Nutritional Rickets
The purpose of this study is: 1. To compare the response of rickets to calcium with and without vitamin D. 2. To assess whether vitamin D increases calcium absorption in calcium defi...
The study will be a large randomized controlled trial to assess the efficacy and safety of neonatal vitamin A supplementation administered to neonates once orally either on the day of birt...
Antenatal Vitamin D3 Dose-finding and Safety Study
This is a preliminary study of oral vitamin D3 supplementation in pregnant and non-pregnant women of reproductive age in Bangladesh. The primary objective of the study is to identify a dos...
Recently it has been documented that vitamin D has important functions in the human body that are unrelated to its primary effects in calcium homeostasis and bone mineralization. In clinic...
